Jagsonpal Pharmaceuticals Limited 507789 Financial and Strategic SWOT Analysis Review

We are sorry but this premium report expired!

This market research, not available anymore on the publisher's website, was withdrawn from our database.

To get an alternative report, you can either :

  • Have a look at the list of documents hereafter
  • Launch a new search below

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

DOWNLOAD THESE REPORTS NOW!

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

  • $ 645
  • Industry report
  • by Firstword Pharma
  • Feb 2015

The potential blockbuster status of Novartis' LCZ696 has seemingly been cemented in the eyes of the Street thanks to solid results from the Phase III PARADIGM-HF study that were presented over the weekend. Indeed, the chronic heart failure agent is believed to represent both a significant growth drive ...

Industries: Pathology | Countries: United States

Newron Pharmaceuticals Spa

Newron Pharmaceuticals Spa

  • $ 55
  • Company report
  • by Wright Investors' Service
  • February 2015
  • 56 pages

A textual analysis of the financial results for Newron Pharmaceuticals Spa compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. A business ...

Industries: Pharmaceutical

COMA 18 Joint Stock Co

COMA 18 Joint Stock Co

  • $ 55
  • Company report
  • by Wright Investors' Service
  • February 2015
  • 55 pages

A textual analysis of the financial results for COMA 18 Joint Stock Co compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. A business description ...

Industries: Pathology

Cuu Long Pharmaceutical Joint Stock Corp

Cuu Long Pharmaceutical Joint Stock Corp

  • $ 55
  • Company report
  • by Wright Investors' Service
  • February 2015
  • 56 pages

A textual analysis of the financial results for Cuu Long Pharmaceutical Joint Stock Corp compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. ...

Industries: Pharmaceutical

Hatay Pharmaceutical JSC

Hatay Pharmaceutical JSC

  • $ 55
  • Company report
  • by Wright Investors' Service
  • February 2015
  • 55 pages

A textual analysis of the financial results for Hatay Pharmaceutical JSC compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. A business ...

Industries: Pharmaceutical

OPC Pharmaceutical JSC

OPC Pharmaceutical JSC

  • $ 55
  • Company report
  • by Wright Investors' Service
  • February 2015
  • 56 pages

A textual analysis of the financial results for OPC Pharmaceutical JSC compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. A business description ...

Industries: Pharmaceutical

Doan Xa Port JSC

Doan Xa Port JSC

  • $ 55
  • Company report
  • by Wright Investors' Service
  • February 2015
  • 55 pages

A textual analysis of the financial results for Doan Xa Port JSC compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. A business description ...

Industries: Over-the-counter Drug

DHG Pharmaceutical JSC

DHG Pharmaceutical JSC

  • $ 55
  • Company report
  • by Wright Investors' Service
  • February 2015
  • 57 pages

A textual analysis of the financial results for DHG Pharmaceutical JSC compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. A business description ...

Industries: Pharmaceutical

Autoimmune Drug Focus FEBRUARY 2015

Autoimmune Drug Focus FEBRUARY 2015

  • $ 1 114
  • Industry report
  • by Espicom Business Intelligence
  • February 2015
  • 28 pages

Industry Trend Analysis - Hyperion Deal Will End DiaPep277 Controversy Industry Trend Analysis - Afrezza's US Launch Will Test Appetite For New Insulin Delivery Systems Industry Brief - Positive Results From Adocia's HinsBet Fast Acting Insulin Formulation In Phase IIa Trial Industry Brief - First Patient ...

Industries: Pathology | Countries: United States, Canada, Europe, World

Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

  • $ 55
  • Company report
  • by Wright Investors' Service
  • February 2015
  • 50 pages

A textual analysis of the financial results for Agios Pharmaceuticals Inc compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. A business ...

Industries: Pharmaceutical

24/7 Customer Service

You can call our customer service 24 hours a day / 7 days a week

  • +1 718 303 2019

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.